Arsenical keratosis
Arsenical keratosis (palms)
SpecialtyDermatology

An arsenical keratosis is a growth of keratin on the skin caused by arsenic,[1]: 725  which occurs naturally in the Earth's crust and is widely distributed in the environment,[2] Arsenical compounds are used in industrial, agricultural, and medicinal substances. Arsenic is also found to be an environmental contaminant in drinking water (well water) and an occupational hazard for miners and glass workers.[3]: 640  Arsenic may also causes other conditions including: Bowen's disease,[4] cardiovascular diseases, developmental abnormalities, neurologic and neurobehavioral disorders, diabetes, hearing loss, hematologic disorders, and various types of cancer.[5] Arsenical keratoses may persist indefinitely, and some may develop into invasive squamous cell carcinoma. Metastatic arsenic squamous cell carcinoma and arsenic-induced malignancies in internal organs such as the bladder, kidney, skin, liver, and colon, may result in death.[5]

Signs and symptoms

Books talk about diffuse ketarosic neoformations in palms and plants, which can evolve into basal cell carcinoma. These neoformations are usually yellowish.

Pathophysiology

Arsenite impairs nucleotide excision repair,[6] and it may also affect gene expression by increasing or decreasing DNA methylation. The high affinity of arsenic for sulfhydryl groups makes keratin-rich cells (e.g., epidermal keratinocytes) a sensitive target for arsenic-induced toxicity. Arsenic has been shown to alter epidermal keratinocyte differentiation processes,[7] induce overexpression of growth factors,[8] and enhance proliferation of human keratinocytes.

Treatment

References

  1. ^ Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). McGraw-Hill. ISBN 0-07-138076-0.
  2. ^ Duker AA, Carranza EJ, Hale M (July 2005). "Arsenic geochemistry and health". Environ Int. 31 (5): 631–41. doi:10.1016/j.envint.2004.10.020. PMID 15910959.
  3. ^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
  4. ^ a b Yerebakan O, Ermis O, Yilmaz E, Basaran E (February 2002). "Treatment of arsenical keratosis and Bowen's disease with acitretin". Int. J. Dermatol. 41 (2): 84–7. doi:10.1046/j.1365-4362.2002.01372.x. PMID 11982642.
  5. ^ a b Tchounwou PB, Centeno JA, Patlolla AK (January 2004). "Arsenic toxicity, mutagenesis, and carcinogenesis--a health risk assessment and management approach" (PDF). Mol. Cell. Biochem. 255 (1–2): 47–55. doi:10.1023/B:MCBI.0000007260.32981.b9. PMID 14971645.
  6. ^ Hartwig A, Groblinghoff UD, Beyersmann D, Natarajan AT, Filon R, Mullenders LH (February 1997). "Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts". Carcinogenesis. 18 (2): 399–405. doi:10.1093/carcin/18.2.399. PMID 9054635.
  7. ^ Kachinskas DJ, Phillips MA, Qin Q, Stokes JD, Rice RH (November 1994). "Arsenate perturbation of human keratinocyte differentiation". Cell Growth Differ. 5 (11): 1235–41. PMID 7848924. Archived from the original on 2013-02-23. Retrieved 2009-02-09.
  8. ^ Germolec DR, Yoshida T, Gaido K, et al. (November 1996). "Arsenic induces overexpression of growth factors in human keratinocytes". Toxicol. Appl. Pharmacol. 141 (1): 308–18. doi:10.1006/taap.1996.0288. PMID 8917704.
  9. ^ Son SB, Song HJ, Son SW (March 2008). "Successful treatment of palmoplantar arsenical keratosis with a combination of keratolytics and low-dose acitretin". Clin. Exp. Dermatol. 33 (2): 202–4. doi:10.1111/j.1365-2230.2007.02596.x. PMID 18039342. Archived from the original on 2013-01-05.
  10. ^ a b Khandpur S, Sharma VK (October 2003). "Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil". J. Dermatol. 30 (10): 730–4. doi:10.1111/j.1346-8138.2003.tb00468.x. PMID 14684956. Archived from the original on 2011-07-22.
  11. ^ Sharma SC, Simpson NB (1983). "Treatment of arsenical keratosis with etretinate". Acta Derm. Venereol. 63 (5): 449–52. PMID 6197851.
  12. ^ Boonchai W (April 2006). "Treatment of precancerous and cancerous lesions of chronic arsenicism with 5% imiquimod cream". Arch Dermatol. 142 (4): 531–2. doi:10.1001/archderm.142.4.531. PMID 16618886.
Categories